Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00470847
Recruitment Status : Completed
First Posted : May 8, 2007
Results First Posted : January 20, 2014
Last Update Posted : May 22, 2014
Brigham and Women's Hospital
Breast Cancer Research Foundation
Information provided by (Responsible Party):
Nancy Lin, MD, Dana-Farber Cancer Institute

Brief Summary:
The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain. Depending upon the participants cancer, they may also have stereotactic radiosurgery (SRS). Lapatinib s a compound that may stop cancer cells from growing abnormally. It is thought that lapatinib might also make cancer cells more sensitive to radiation. This drug has been used in other research studies in women with breast cancer, and information from those other research studies suggests that lapatinib may help to shrink or stabilize breast tumors both inside the brain and outside the brain.

Condition or disease Intervention/treatment Phase
Breast Cancer Brain Metastases Drug: Lapatinib Procedure: Whole Brain Radiation Drug: Herceptin Phase 1

Detailed Description:
  • Participant's will be given a study medication-dosing calendar for each treatment cycle. Each treatment cycle lasts four weeks. On the first day of the treatment cycle, participants will take 1 lapatinib orally twice per day, 12 hours apart. After the first day, lapatinib will be taken once a day in the morning.
  • Whole brain radiation treatments will begin approximately 1-8 days after the first dose of lapatinib. The radiation treatments will follow standard guidelines and will be supervised by a radiation oncologist. Radiation will be given in 15 treatments over a period of three weeks.
  • Some participants will also undergo stereotactic radiosurgery (SRS). SRS is a highly focused and intense form of radiation treatment generally done as an outpatient procedure in a single treatment.
  • After whole brain radiation treatments are completed, lapatinib will be continued at the same dose for one more week. After that, the lapatinib dose may change. In addition at the same time, Herceptin will be started. Participants will continue with both lapatinib and herceptin together as long as there is evidence that they are benefitting from it.
  • During all treatment cycles participants will have a physical exam and be asked general questions about their health. Photographs will be taken of the tumor, if visible, to assess the response of the tumor to the treatment. An assessment of the tumor by CT scan of the body, and MRI imaging of the brain will be performed every two months. An assessment of heart function by MUGA scan or echocardiogram will be performed every 8 weeks. The participant will also be asked to complete a brief questionnaire measuring quality of life and asking about symptoms related to the cancer at baseline, 6 months, and one year. Blood tests will be performed every 4 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
Study Start Date : April 2007
Actual Primary Completion Date : December 2009
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Lapatinib,Whole Brain Radiation,Herceptin
Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly
Drug: Lapatinib
Orally twice daily
Other Name: Tykerb

Procedure: Whole Brain Radiation
15 treatments over a period of 3 weeks

Drug: Herceptin
Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
Other Name: Trastuzumab

Primary Outcome Measures :
  1. The Maximum Tolerated Dose of Lapatinib When Combined With Cranial Radiation in Patients With CNS Metastases From HER2-positive Breast Cancer. [ Time Frame: 5 Years ]
    The maximum tolerated dose is defined as :The highest dose of a drug or treatment that does not cause unacceptable side effects.

Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 5 years ]
    Progression Free Survival is the time from date of start of treatment to the date of the first documented progression or death due to any cause. If a patient has not progressed or died, progression free survival is censored at the time of last tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20 % increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

  2. Objective Response Rate in Central Nervous System Sites [ Time Frame: 5 years ]
    Objective Response Rate was defined using volumetric response as the following: Complete Response (CR) is the disappearance of all target lesions, stable/responsive non-target lesions, and no new lesions. Partial response (PR) is at least a 50% reduction in the sum of the target lesions, stable/responsive non-target lesions, and no new lesions. Stable Disease (SD) is neither CR PR or Progressive Disease (PD). And Progressive Disease (PD) is at least 40% increase in sum of target lesionsor the appearance of any new lesion >=6mm in the longest dimension. If a patient progressed in a non-central nervous system(CNS) site first, died, or withdrew from the study for any reason after the first dose of drug was administered, and before a CR or PR in the central nervous system was determined, she was considered a CNS non-responder.

  3. Percentage of Participants Having Central Nervous System as the Site of the First Progression [ Time Frame: 5 years ]
  4. Percentage of Participants Having Non-Central Nervous System Sites as the Site of First Progression [ Time Frame: 5 years ]
  5. Overall Survival [ Time Frame: Participants were followed for an average of 3.8 years ]
    Overall average length of participant survival after protocol initiation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically-confirmed invasive breast cancer
  • HER2 overexpressing breast cancer defined as 3+ staining by immunohistochemistry, or HER2 gene amplification by FISH
  • At least one parenchymal brain metastasis
  • Disease progression in the CNS as assessed by at least one of the following; new neurological signs or symptoms; new lesion(s) in the CNS on an imaging study; progressive lesions on an imaging study
  • At least two weeks since prior radiotherapy, last chemotherapy, immunotherapy, biologic therapy, or major surgery for cancer
  • 18 years of age or older
  • Life expectancy of greater than 12 weeks
  • ECOG performance status 0-2
  • Normal organ and marrow function as described in the protocol
  • Left ventricular ejection fraction > 50%
  • Able to swallow and retain oral medications

Exclusion Criteria:

  • Prior WBRT
  • Receiving any other investigational agents
  • Concurrent chemotherapy, immunotherapy, biologic therapy or hormonal therapy for treatment of their cancer
  • History of grade 3 or 4 allergic reactions attributed to compounds of similar chemical or biologic composition to herceptin or lapatinib
  • Leptomeningeal carcinomatosis as the only site of CNS involvement
  • Concurrent treatment with medications that are either inducers of inhibitors of CYP3A4
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or active ulcerative colitis
  • History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents
  • Other known contraindication to MRI
  • Uncontrolled intercurrent illness
  • History of other active malignancy except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix
  • Pregnant or breastfeeding women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00470847

Layout table for location information
United States, Indiana
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Nancy Lin, MD
Brigham and Women's Hospital
Breast Cancer Research Foundation
Layout table for investigator information
Principal Investigator: Nancy Lin, MD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Nancy Lin, MD, Principal Investigator, Dana-Farber Cancer Institute Identifier: NCT00470847    
Other Study ID Numbers: 06-356
First Posted: May 8, 2007    Key Record Dates
Results First Posted: January 20, 2014
Last Update Posted: May 22, 2014
Last Verified: April 2014
Keywords provided by Nancy Lin, MD, Dana-Farber Cancer Institute:
breast cancer
radiation therapy
stereotactic radiosurgery
whole brain radiation
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasm Metastasis
Brain Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action